ONWARD Medical Reports Significant Progress in 2024
ONWARD Medical N.V. (NASDAQ: ONWD), a company recognized for its pioneering medical therapies aimed at restoring movement and independence for those with spinal cord injuries, has recently shared its financial results for the first half of 2024 along with a detailed business update. The company highlighted notable achievements during this period, showcasing both strategic advancements and financial growth.
Highlights of the Half-Year Results
The first half of 2024 was a remarkable time for ONWARD Medical. They submitted a De Novo application for their investigational ARC-EX System to the FDA, published pivotal results from the Up-LIFT study in a leading medical journal, and secured over EUR 52.5 million in growth financing from Runway Growth Capital. CEO Dave Marver expressed enthusiasm about the progress, particularly in the field of brain-computer interfaces (BCI), which focus on developing therapies to restore movement following spinal cord injuries.
Clinical and Development Advancements
- In January, the company expanded its HemON clinical feasibility study by incorporating Sint Maartenskliniek in the Netherlands, as part of its preparations for a global pivotal trial called Empower BP, which aims to enhance blood pressure control in SCI patients.
- In February, the FDA awarded Breakthrough Device Designation to the ARC-BCI System, recognizing its innovative integration of BCI technology with therapeutic solutions.
- By March, ONWARD Medical became one of only two BCI companies to join the FDA's Total Product Lifecycle Advisory Program (TAP), which is designed to facilitate the commercialization of their technologies.
- In April, they took a significant step by submitting a De Novo application to the FDA to market their non-invasive ARC-EX System, with expectations for clearance by late 2024.
- May saw the publication of their Up-LIFT trial results, which showed significant improvements in upper limb function for individuals living with chronic tetraplegia.
Science and Intellectual Property Milestones
- During the first half of 2024, ONWARD Medical was granted 30 new patents, bringing its total to over 270 patents, which reinforces its leading position in spinal cord injury therapies.
Corporate Strategies and Financial Status
In March, ONWARD Medical successfully completed a €20 million equity financing round, which further strengthened its cash reserves to support ongoing product development and clinical studies. Additionally, they secured a debt financing agreement for up to EUR 52.5 million, with plans to utilize these funds for upcoming commercial activities and general corporate purposes.
- As of June 30, 2024, the company reported an operating loss of EUR 18.7 million, consistent with the previous period, while maintaining a strong cash position of EUR 32.1 million, an increase from EUR 29.8 million at the end of 2023.
Future Outlook and Anticipated Milestones
Looking forward, ONWARD Medical is committed to maintaining its steady progress. The company aims to secure FDA clearance for the launch of its ARC-EX System in Q4 2024 and is actively building a dedicated sales and service team to support this launch.
- They also expect a peer-reviewed publication detailing the outcomes of the first ten patients implanted with the ARC-IM Therapy, which focuses on blood pressure stability following spinal cord injury.
- Preparations are in progress for the international Empower BP trial, associated with the ARC-IM Therapy, with significant milestones anticipated by late 2024 and early 2025.
- Continued development of the ARC-BCI System remains a priority, bolstered by new funding from recognized foundations and significant partnerships.
About ONWARD Medical
With over a decade of groundbreaking research behind it, ONWARD Medical develops ARC Therapy, which has received multiple Breakthrough Device Designations from the FDA. This therapy employs tailored spinal cord stimulation delivered through its ARC-EX and ARC-IM platforms. Results from the Up-LIFT trial have underscored the effectiveness of ARC-EX Therapy in improving upper limb function.
Based in Eindhoven with an office in Boston, ONWARD Medical is dedicated to advancing rehabilitation for spinal cord injury recovery and plans to broaden its clinical studies to address mobility challenges across various conditions, including Parkinson's disease.
Frequently Asked Questions
What are the key financial results for ONWARD Medical in the first half of 2024?
ONWARD Medical reported an operating loss of EUR 18.7 million while maintaining a positive cash balance of EUR 32.1 million by the end of June 2024.
What advancements did ONWARD Medical make in BCI technology?
They achieved Breakthrough Device Designation for the ARC-BCI System and became a participant in the FDA's TAP program for streamlined commercialization.
What is the relevance of the Up-LIFT study published in Nature Medicine?
The Up-LIFT study reported significant improvements in upper limb function for patients with chronic tetraplegia, marking a significant milestone for ONWARD Medical.
How much funding has ONWARD Medical secured recently?
The company secured EUR 52.5 million in growth financing from Runway Growth Capital along with a €20 million equity financing round completed earlier in 2024.
What is ONWARD Medical's primary goal for the remainder of 2024?
The primary goal is to obtain FDA clearance for the ARC-EX System and prepare for its commercial launch while continuing to develop their innovative therapies.
